查看購物車
  • English
  • Japanese
生物保存市場－全球及區域分析：按產品類型、應用、最終用戶和地區分類－分析與預測（2025-2035）
市場調查報告書
商品編碼
1956054

生物保存市場－全球及區域分析：按產品類型、應用、最終用戶和地區分類－分析與預測（2025-2035）

Biopreservation Market - A Global and Regional Analysis: Product Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 128 Pages | 商品交期: 1-5個工作天內

價格

預計到 2024 年，全球生物保存市場規模將達到 43.163 億美元，到 2035 年將顯著成長至 151.854 億美元。

這意味著從 2025 年到 2035 年，複合年成長率將達到 12.61%。

關鍵市場統計數據
預測期 2025-2035
截至2025年的估值 46.318億美元
2035 年預測 151.854億美元
複合年成長率 12.61%

這一成長是由細胞和基因療法的日益普及、生物樣本庫和基因庫的快速發展以及對用於研究和臨床應用的高價值生物材料長期儲存日益成長的需求所推動的。

由於生物醫學研究、再生醫學、臨床試驗和先進治療藥物生產等領域產生的生物樣本數量不斷成長，生物保存市場正經歷顯著的成長動能。這些應用中使用的細胞、組織、血液和遺傳物質需要檢驗的保存方案，以確保其在儲存、運輸和後續使用過程中保持活性、穩定性和功能完整性。隨著個人化醫療、群體基因組學和先進治療方法的興起，可靠的生物保存技術已成為支撐不斷發展的醫療保健和生命科學生態系統的關鍵基礎架構。

技術創新正在重塑生物保存產業，冷凍保存介質、可控冷凍系統、自動化和機器人輔助的低溫儲存以及數位化整合監測解決方案的進步，提高了樣本品質、擴充性和合規性。儘管成長前景強勁，但該市場仍面臨許多挑戰，包括高額的資本投資、高能耗的儲存系統以及與冷凍庫故障和低溫供應中斷相關的營運風險。然而，對生物銀行基礎設施、再生醫學計畫和全球低溫運輸物流的持續投資預計將在長期內支撐市場擴張。

市場概覽

全球生物保存市場已從傳統的冷藏方法發展成為一個技術先進的生態系統，支持在研究、臨床和商業環境中保存細胞、組織、器官和遺傳物質。市場參與企業正致力於開發高性能生物保存培養基、自動化低溫儲存平台和數位化監控系統，以滿足現代生物銀行和先進治療工作流程日益成長的品質、可追溯性和合規性要求。

生物保存解決方案提供者、生物樣本庫、製藥和生物技術公司、合約研發生產機構 (CDMO) 以及學術研究機構之間的策略聯盟正在加速整個保存流程的創新和標準化。隨著生物樣本採集規模和複雜性的不斷成長，生物保存正逐漸成為支撐精準醫療、細胞和基因治療生產以及大規模縱向研究的核心基礎設施。這些結構性變化正將生物保存定位為全球生命科學和醫療保健生態系統中的關鍵成長市場。

對產業的影響

受細胞和基因療法快速發展、大規模生物銀行庫建設以及對高價值生物樣本長期保存需求日益成長的推動，全球生物保存市場正經歷著顯著的產業變革。生物保存培養基、低溫儲存系統、自動化平台和低溫運輸物流等關鍵產業領域的參與企業，在確保用於研究、臨床試驗和商業生產的細胞、組織、血液和遺傳物質的可靠保存方面發揮著核心作用。這些解決方案對於細胞和基因療法開發、再生醫學、生物銀行和精準醫療等應用至關重要，因為解凍後樣本的活性、功能和完整性直接影響後續處理的結果。

冷凍保存介質、可控冷凍技術、自動化和機器人冷凍保存系統以及數位化整合監測系統的進步，正在提高營運效率、減少樣本損失並加強監管合規性。生物保存技術透過在全球研發和生產網路中實現一致的存儲，支持可擴展的臨床開發、分散式治療藥物生產和長期縱向研究。該市場與個人化醫療和先進療法的契合進一步放大了其產業影響力，使生物保存技術成為支持下一代生命科學創新和醫療保健服務的基礎基礎設施。

市場區隔:

細分1：按產品

  • 培養基
  • 裝置

培養基細分市場在生物保存市場（按產品分類）主導

根據產品類型，培養基預計將在生物保存市場中佔據主導地位。由於其在維持生物材料（包括細胞、組織、遺傳物質以及用於細胞和基因治療、生物生物銀行和再生醫學的生物製藥）的活力、穩定性和功能完整性方面發揮著至關重要的作用，預計培養基將佔據相當大的市場佔有率。隨著生物技術和生物製藥行業的持續擴張，由於細胞療法和再生醫學的快速發展，對高性能生物保存培養基的需求也在穩步成長。 CAR-T療法和幹細胞療法等先進治療方法高度依賴冷凍保存技術，以在生產、儲存和運輸過程中維持細胞品質。值得注意的是，大多數獲得FDA已通過核准的細胞和基因療法都依賴冷凍保存的原料或最終產品，這凸顯了最佳化解凍後細胞活力和功能的重要性。

細分 2：按應用

  • 研究用途
  • 治療用途
  • 其他

預計科研應用將主導生物保存市場（按應用領域分類）。

預計研究應用將推動生物保存市場的發展，其驅動力包括生物醫學和基因組學研究的日益成長、生物樣本庫的快速擴張以及臨床試驗和藥物研發活動的活性化。在研究環境中，生物保存培養基和保存系統對於維持生物材料在長期儲存、運輸和重複實驗使用過程中的活性、穩定性和分子完整性至關重要。例如，在幹細胞研究中，人類多功能細胞（hPSCs）通常使用專門的生物保存培養基進行保存，以維持其多功能和分化潛能，即使在解凍後也能如此，這對於再生醫學和發育生物學研究至關重要。同樣，在基因組學和人群研究中，大型生物樣本庫依賴檢驗的生物保存解決方案來保存DNA、RNA、組織和細胞，從而確保樣本的一致性並適用於縱向研究。隨著全球調查計畫的擴展，數據可重複性和樣本品質變得越來越重要，研究應用中對可靠的生物保存解決方案的需求依然強勁，這鞏固了該領域在生物保存市場的主導地位。

細分3：按最終用戶

  • 生物樣本庫和基因庫
  • 醫院
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 其他（私人診所、學術機構、政府機構）

生物樣本庫和基因庫將推動生物保存市場（按最終用戶分類）的發展。

由於生物樣本庫和基因庫在基因組研究、藥物發現、臨床試驗和個人化醫療中發揮核心作用，預計它們將推動生物保存市場的發展。這些機構負責長期保存高價值生物材料，包括細胞、組織、血液和遺傳樣本，這些材料是疾病研究、生物標記鑑定和治療方法開發的基礎。基因測序、人群調查和生物技術研究的快速發展顯著增加了對可靠生物保存解決方案的需求，這些解決方案能夠長期維持樣本的完整性、活性和分子穩定性。此外，來自政府、研究聯盟和私人機構的持續投資正在推動全球生物樣本庫和基因庫的擴張，為再生醫學計畫、大規模流行病學研究和多中心臨床試驗提供支援。隨著這些樣本庫規模和複雜性的不斷成長，對高品質生物保存培養基、低溫儲存系統和監測基礎設施的需求也在穩步成長。

細分 4：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 其他地區

北美地區在生物保存市場中處於領先地位（按地區分類）。

全球生物保存市場正經歷強勁成長，這主要得益於細胞和基因療法研發管線的不斷擴展、大規模生物銀行庫建設以及對高價值生物材料長期儲存需求的日益成長。北美預計將繼續保持領先地位，這得益於其先進的醫療和研究基礎設施、細胞和基因療法的早期應用以及對生物樣本庫和再生醫學的大量投資。預計到2035年，該地區的市場規模將達到62.433億美元，主要由對生物保存培養基、低溫儲存系統和符合GMP標準的低溫運輸服務的持續需求所驅動。北美的主導地位也得益於眾多大型生物技術和製藥公司、成熟的學術和臨床研究機構以及支持先進治療方法的健全法規結構。此外，臨床試驗的增加、細胞和基因療法（CGT）的商業化以及國家和私人生物銀行計畫的不斷擴展，持續推動對可靠且擴充性的生物保存解決方案的長期需求，從而鞏固了該地區的市場主導地位。

生物保存市場最新趨勢

  • 2025年11月，BioLife Solutions公司開設了艾比·J·馬修斯生物保護卓越中心。該中心位於公司位於博塞爾的擴建總部內，以公司創始成員、執行副總裁兼首席科學官艾比·J·馬修斯博士的名字命名。
  • 2025年10月，Cryoport在法國羅浮宮開設了一座佔地55,000平方英尺的全新全球供應鏈中心。該中心地理位置位置，毗鄰戴高樂機場，將協助先進療法的全球分銷。這座先進的設施提供端到端的溫控供應鏈解決方案，為生技藥品和其他溫度敏感型材料帶來無與倫比的便利性和可靠性。
  • 2025年4月，BioLife Solutions, Inc.收購了Pantera Cryosolutions, Inc.（簡稱「Pantera」），後者是一家私人企業，致力於開發基於其專有「冰重結晶抑制劑（IRI）」技術的先進冷凍保存解決方案。此次收購進一步鞏固了BioLife在生物保存領域的領先地位，拓展了其耗材解決方案產品組合，並為經營團隊注入了寶貴的科學專業知識。

需求——促進因素、挑戰與機遇

市場促進因素

細胞和基因治療及再生醫學的快速發展—細胞和基因治療（CGT）以及再生醫學的快速發展是生物保存市場的主要結構性促進因素。根據國際細胞和基因治療學會（ISCT）發布的《2024年全球監管報告》，目前全球有超過3000個CGT計畫正在研發中，後期臨床試驗活動和監管核准不斷增加。這些治療方法在整個價值鏈中高度依賴冷凍保存材料，包括白血球分離術、基因修飾細胞中間體、病毒載體、細胞庫和冷凍最終藥物產品。同行評審的研究表明，冷凍保存的原料（例如白血球分離術材料）在解凍後可保持90%以上的細胞活力，同時功能性能與新鮮材料相當，這證明冷凍保存是一種不遜色且可擴展的方法。細胞生長激素（CGT）產量的增加和商業化的加​​速推進，帶動了對高性能冷凍保存介質、可控冷凍技術、自動化低溫儲存、超低溫和液態氮平台以及符合GMP標準的低溫運輸物流的需求。這項變革正將生物保存技術轉變為支援CGT開發、生產和全球分銷的核心平台。

市場挑戰

先進生物保存基礎設施的高昂購買和營運成本——高昂的購買和營運成本仍然是生物保存市場的主要阻礙因素，尤其是在先進的低溫儲存基礎設施方面。超低溫冷凍庫、液態氮儲存系統、可控冷凍設備和監控基礎設施都需要大量的初始投資和持續的維護。超低溫冷凍庫的能耗極高，每天耗電高達20千瓦時，導致每年的電力和空調成本居高不下，對於大型設施而言更是如此。此外，高性能低溫冷凍庫的價格通常高達數萬美元，這無疑為小規模機構設置了進入門檻。液態氮補充、警報系統、校準和維護合約等持續成本進一步增加了總擁有成本。這些財務壓力在電力供應不穩定、液態氮分銷網路有限的中低收入地區尤為突出，阻礙了最佳實踐系統的應用。因此，許多機構繼續依賴老舊、低效的設備，這損害了樣本的完整性，並限制了它們參與國際研究和先進治療計畫。

市場機遇

利用人工智慧 (AI) 提升診斷能力－將人工智慧 (AI) 引入骨髓惡性腫瘤的診斷流程，為全球檢測市場帶來了巨大的成長機會。 AI 技術已展現出提升診斷準確性和速度的能力，尤其是在傳統方法有其限制的複雜病例中。例如，AI 演算法在鑑別罕見血液癌症（如原發性纖維化和原發性血小板增多症）方面表現出色，為臨床醫生和病理學家提供了重要的支持。將 AI 整合到診斷工作流程中，能夠提高診斷準確性、最佳化臨床決策並提升病患管理效率。此外，AI 能夠快速分析大量複雜的醫療數據，從而實現更快、更可靠的診斷，並有望加快臨床試驗的患者招募和新治療方法的研發。隨著醫療保健系統的不斷發展，並越來越依賴 AI 技術來管理日益複雜的醫療數據，對 AI 驅動的診斷解決方案的需求預計將會成長。透過投資人工智慧技術或建立策略合作夥伴關係來增強這些能力的診斷公司，將在快速發展的生物保存市場中確立主導地位，並推動該領域的創新和成長。

全球生物保存市場可細分為多個關鍵領域，包括產品類型、應用、最終用戶和區域市場。本報告透過分析哪些細分領域佔據最大市場佔有率以及哪些細分領域具有成長潛力，為希望創新和拓展其生物保存產品及技術組合的企業提供寶貴的見解。

策略聯盟、合資企業和擴張預計將在生物保存市場的成長中發揮核心作用。生物保存解決方案提供者、生物樣本庫、製藥和生物技術公司以及研究機構之間的重大發展和合作關係構成了不斷演變的市場動態的關鍵組成部分。

生物保存市場競爭異常激烈，許多成熟企業提供種類繁多的生物保存介質、設備和服務。主要市場參與企業正積極研發和推出先進的冷凍保存技術、自動化和數位化監控解決方案，以實現差異化競爭並鞏固市場地位。

調查方法

市場設計與檢驗中的關鍵考慮因素與假設

  • 為了估算全球市場規模，我們考慮了 2024 年至 2035 年這段期間，其中 2024 年為基準年，2025 年至 2035 年為預測期。
  • 本研究的範圍是基於來自各行業的專家的全面意見，包括生物樣本庫和基因庫、製藥和生物技術公司、細胞和基因治療開發商、醫院、學術研究機構和合約研究組織。
  • 預計未來生物保藏產品的市場佔有率將顯著成長，該預測是基於對現有解決方案的歷史分析。
  • 各公司的收入均根據其 2024 財政年度的年度報告收集。對於私人公司，公司收入根據一手調查數據、資金籌措歷史、市場聯繫狀況和業務績效進行估算。
  • 本報告基於現有市售生物保存介質和設備繪製了市場圖。報告還識別並介紹了該領域提供關鍵產品和服務的主要企業。

主要市場參與企業及競爭格局概述

本次評選的公司是根據對公司覆蓋範圍、產品系列和市場滲透率的分析所得出的資訊而選定的。

該市場的主要企業包括：

  • BioLife Solutions, Inc.
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Azenta, Inc.
  • Bio-Techne
  • Cryoport Systems, LLC
  • Danaher Corporation (Cytiva)
  • PHC Corporation
  • Alpha Teknova, Inc.
  • Eppendorf SE
  • ThermoGenesis
  • OriGen Biomedical, Inc.
  • X-Therma, Inc.
  • STEMCELL Technologies
  • IC Biomedical, LLC

目錄

執行摘要

第1章 全球生物保存市場：產業展望

  • 市場概覽
    • 市場概覽
    • 供應鏈分析
  • 市場趨勢
    • 影響分析
    • 快速採用先進的冷凍保存技術
    • 人工智慧與實驗室資訊管理系統在生物銀行和生物檢體管理中的整合日益加深
  • 監管狀態
    • 美國
    • 歐洲
    • 亞太地區
  • 市場動態
    • 促進因素、挑戰和機會：評估當前和未來的影響
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章 產品類型

  • 概述
    • 裝置
    • 培養基

第3章 應用

  • 概述
    • 研究用途
    • 治療用途
    • 其他

第4章 最終用戶

  • 概述
    • 生物樣本庫和基因庫
    • 醫院
    • 製藥和生物技術公司
    • 受託研究機構（CRO）
    • 其他

第5章 區域

  • 區域概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 競爭標竿分析與公司概況

  • 2023-2025年主要策略與發展
  • 2025年主要發展趨勢分析（依公司分類）
  • 公司簡介
    • BioLife Solutions, Inc.
    • Thermo Fisher Scientific Inc.
    • Sartorius AG
    • Azenta, Inc.
    • Bio-Techne
    • Cryoport Systems, LLC
    • Danaher Corporation (Cytiva)
    • PHC Corporation
    • Alpha Teknova, Inc.
    • Eppendorf SE
    • ThermoGenesis
    • OriGen Biomedical, Inc.
    • X-Therma, Inc.
    • STEMCELL Technologies
    • IC Biomedical, LLC

第7章調查方法

Product Code: BHL3415SA

This report can be delivered within 1 working day.

Introduction of the Biopreservation Market

The global biopreservation market, initially valued at $4,316.3 million in 2024, is projected to witness substantial growth, surging to $15,185.4 million by 2035, marking a remarkable compound annual growth rate (CAGR) of 12.61% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$4,631.8 Million
2035 Forecast$15,185.4 Million
CAGR12.61%

This growth is driven by the expanding adoption of cell and gene therapies, the rapid proliferation of biobanks and gene banks, and the increasing need for long-term preservation of high-value biological materials across research and clinical applications.

The biopreservation market is experiencing significant momentum due to the growing volume of biological samples generated from biomedical research, regenerative medicine, clinical trials, and advanced therapy manufacturing. Cells, tissues, blood, and genetic materials used in these applications require validated preservation solutions to maintain viability, stability, and functional integrity during storage, transportation, and downstream use. As personalized medicine, population genomics, and advanced therapeutics gain traction, reliable biopreservation has become a critical enabling infrastructure supporting these evolving healthcare and life sciences ecosystems.

Technological advancements are reshaping the biopreservation landscape, with innovations in cryopreservation media, controlled-rate freezing systems, automated and robotics-enabled cryogenic storage, and digitally integrated monitoring solutions improving sample quality, scalability, and regulatory compliance. Despite strong growth prospects, the market faces challenges such as high capital investment requirements, energy-intensive storage systems, and operational risks associated with freezer failures and cryogenic supply disruptions. Nevertheless, continued investments in biobanking infrastructure, regenerative medicine programs, and global cold-chain logistics are expected to sustain long-term market expansion.

Market Introduction

The global biopreservation market has evolved from conventional cold storage practices into a technologically advanced ecosystem supporting the preservation of cells, tissues, organs, and genetic material across research, clinical, and commercial environments. Market participants are increasingly focusing on developing high-performance biopreservation media, automation-ready cryogenic storage platforms, and digitally enabled monitoring systems to meet the rising quality, traceability, and compliance requirements of modern biobanking and advanced therapy workflows.

Strategic collaborations between biopreservation solution providers, biobanks, pharmaceutical and biotechnology companies, CDMOs, and academic research institutions are accelerating innovation and standardization across preservation workflows. As the scale and complexity of biospecimen collections continue to increase, biopreservation is emerging as a core infrastructure layer enabling precision medicine, cell and gene therapy manufacturing, and large-scale longitudinal research. These structural shifts are positioning biopreservation as a critical growth market within the global life sciences and healthcare ecosystem.

Industrial Impact

The global biopreservation market has witnessed significant industrial impact, driven by the rapid expansion of cell and gene therapies, large-scale biobanking initiatives, and the growing need for long-term storage of high-value biological materials. Key industry participants across biopreservation media, cryogenic storage systems, automation platforms, and cold-chain logistics play a central role in enabling reliable preservation of cells, tissues, blood, and genetic material used in research, clinical trials, and commercial manufacturing. These solutions are critical across applications such as cell and gene therapy development, regenerative medicine, biobanking, and precision medicine, where maintaining post-thaw viability, functionality, and sample integrity directly affects downstream outcomes.

Advances in cryopreservation media, controlled-rate freezing, automated and robotics-enabled cryogenic storage, and digitally integrated monitoring systems are improving operational efficiency, reducing sample loss, and strengthening regulatory compliance. By enabling consistent preservation across global research and manufacturing networks, biopreservation technologies support scalable clinical development, decentralized therapy manufacturing, and long-term longitudinal studies. The market's industrial impact is further amplified by its alignment with personalized medicine and advanced therapeutics, positioning biopreservation as a foundational infrastructure that underpins next-generation life sciences innovation and healthcare delivery.

Market Segmentation:

Segmentation 1: By Product

  • Media
  • Equipment's

Media Segment to Dominate the Biopreservation Market (by Product)

In terms of product, the media segment is expected to dominate the biopreservation market, accounting for a significant share due to its indispensable role in preserving the viability, stability, and functional integrity of biological materials, including cells, tissues, genetic material, and biopharmaceutical products used across cell and gene therapies, biobanking, and regenerative medicine. As the biotechnology and biopharmaceutical sectors continue to expand, alongside the rapid growth of cell-based and regenerative therapies, demand for high-performance biopreservation media is increasing steadily. Advanced therapies such as CAR-T and stem cell treatments rely heavily on cryopreservation to maintain cell quality throughout manufacturing, storage, and transport. Notably, a majority of FDA-approved cell and gene therapies depend on cryopreserved inputs or final products, underscoring the critical importance of optimizing post-thaw viability and functionality.

Segmentation 2: By Application

  • Research Applications
  • Therapeutic Applications
  • Other Applications

Research Application to Dominate the Biopreservation Market (by Application)

Research applications are expected to dominate the biopreservation market, driven by the growing volume of biomedical and genomic research, the rapid expansion of biobanks, and increasing activity in clinical trials and drug discovery. In research settings, biopreservation media and storage systems are essential to maintain the viability, stability, and molecular integrity of biological materials during long-term storage, transportation, and repeated experimental use. For example, in stem cell research, human pluripotent stem cells (hPSCs) are routinely preserved using specialized biopreservation media to retain pluripotency and differentiation potential after thawing, which is critical for regenerative medicine and developmental biology studies. Similarly, in genomic and population-based research, large-scale biobanks rely on validated biopreservation solutions to store DNA, RNA, tissues, and cells, ensuring sample consistency and suitability for longitudinal studies. As research programs scale globally and emphasize data reproducibility and sample quality, demand for reliable biopreservation solutions in research applications continues to remain strong, reinforcing this segment's leading position in the biopreservation market.

Segmentation 3: By End User

  • Biobanks and Genebanks
  • Hospitals
  • Pharmaceutical & Biotech Companies
  • Contract Research Organizations (CROs)
  • Others (Private Clinics, Academic Institutions, Government)

Biobanks and Genebanks to Dominate the Biopreservation Market (by End User)

Biobanks and gene banks are expected to dominate the biopreservation market due to their central role in genomic research, drug discovery, clinical trials, and personalized medicine. These institutions are responsible for the long-term storage of high-value biological materials, including cells, tissues, blood, and genetic samples, which form the foundation for disease research, biomarker identification, and therapeutic development. The rapid growth of genomic sequencing, population-scale studies, and biotechnology research has significantly increased the need for reliable biopreservation solutions that can maintain sample integrity, viability, and molecular stability over extended periods. In addition, sustained investments from governments, research consortia, and private organizations are driving the expansion of biobanks and gene banks globally, supporting regenerative medicine programs, large-scale epidemiological studies, and multicenter clinical trials. As these repositories continue to scale in size and complexity, demand for high-quality biopreservation media, cryogenic storage systems, and monitoring infrastructure is rising steadily.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

North America to Dominate the Biopreservation Market (by Region)

The global biopreservation market is experiencing strong growth, driven by expanding cell and gene therapy pipelines, large-scale biobanking initiatives, and increasing demand for long-term storage of high-value biological materials. North America is expected to remain the dominant region, supported by its advanced healthcare and research infrastructure, early adoption of cell and gene therapies, and significant investments in biobanks and regenerative medicine. The region's market size is projected to reach $6,243.3 million by 2035, underpinned by sustained demand for biopreservation media, cryogenic storage systems, and GMP-compliant cold-chain services. North America's leadership is further reinforced by the presence of leading biotechnology and pharmaceutical companies, well-established academic and clinical research institutions, and strong regulatory frameworks supporting advanced therapies. In addition, the growing volume of clinical trials, commercialization of CGTs, and expansion of national and private biobanking programs continue to drive long-term demand for reliable and scalable biopreservation solutions, solidifying the region's market dominance.

Recent Developments in the Biopreservation Market

  • In November 2025, BioLife Solutions, Inc. opened the Aby J. Mathew Center for Biopreservation Excellence. Located at the company's expanded headquarters in Bothell, the Center is named in honor of Aby J. Mathew, PhD, a founding team member of BioLife Solutions and the company's Executive Vice President and Chief Scientific Officer.
  • In October 2025, Cryoport, Inc. opened its new 55,000-square-foot Global Supply Chain Center in Louvres, France, strategically located near Charles de Gaulle Airport to enhance global delivery of advanced therapies. The state-of-the-art facility provides end-to-end, temperature-controlled supply chain solutions, offering unparalleled access and reliability for biologics and other temperature-sensitive materials.
  • In April 2025, BioLife Solutions, Inc. acquired the privately held PanTHERA CryoSolutions, Inc. ("PanTHERA"), a developer of advanced cryopreservation solutions built on proprietary Ice Recrystallization Inhibitor ("IRI") technology. This acquisition further solidifies BioLife's leadership in biopreservation, expands its portfolio of consumable solutions, and adds valuable scientific expertise to its management team.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Expansion of Cell and Gene Therapies and Regenerative Medicine: The rapid expansion of cell and gene therapies (CGTs) and regenerative medicine is a major structural driver of the biopreservation market. According to the 2024 Global Regulatory Report by the International Society for Cell and Gene Therapy (ISCT), more than 3,000 CGT programs are currently in development globally, with increasing late-stage clinical activity and regulatory approvals. These therapies depend heavily on cryopreserved materials across the entire value chain, including leukapheresis collections, engineered cell intermediates, viral vectors, cell banks, and frozen final drug products. Peer-reviewed studies demonstrate that cryopreserved inputs, such as leukapheresis material, can achieve post-thaw viability of 90% or higher while maintaining functional performance comparable to fresh material, validating cryopreservation as a non-inferior and scalable approach. As CGT manufacturing volumes rise and commercialization accelerates, demand is increasing for high-performance cryomedia, controlled-rate freezing, automated cryogenic storage, ultra-low-temperature and liquid nitrogen platforms, and GMP-compliant cold-chain logistics. This shift is transforming biopreservation into a core enabler of CGT development, manufacturing, and global distribution.

Market Challenges

High Capital and Operating Costs of Advanced Biopreservation Infrastructure: High capital and operating costs remain a major restraint on the biopreservation market, particularly for advanced cryogenic infrastructure. Ultra-low-temperature freezers, liquid nitrogen storage systems, controlled-rate freezers, and monitoring infrastructure require significant upfront investment and ongoing maintenance. ULT freezers are highly energy intensive, consuming up to 20 kWh per day, which translates into substantial annual electricity and HVAC costs, especially for facilities operating at scale. In addition, high-performance cryogenic freezers are typically priced in the tens of thousands of dollars, creating a clear entry barrier for smaller institutions. Recurring expenses for liquid nitrogen refills, alarm systems, calibration, and service contracts further increase total cost of ownership. These financial pressures are most acute in low- and middle-income regions, where unstable power supply and limited LN2 distribution networks restrict adoption of best-practice systems. As a result, many institutions continue to rely on aging, lower-performance equipment, which can compromise sample integrity and limit participation in global research and advanced therapy programs.

Market Opportunities

Utilizing Artificial Intelligence (AI) to Enhance Diagnostic Capabilities: The incorporation of artificial intelligence (AI) into the diagnostic process for hematologic malignancies represents a significant growth opportunity in the global testing market. AI technologies have demonstrated their ability to improve diagnostic accuracy and speed, particularly in complex cases where traditional methods may fall short. For example, AI-powered algorithms have shown exceptional performance in distinguishing between rare blood cancers such as primary myelofibrosis and essential thrombocythemia, providing critical support to clinicians and pathologists. The integration of AI into diagnostic workflows can enhance the precision of diagnoses, improve clinical decision-making, and streamline patient management. Moreover, AI's ability to analyze large volumes of complex medical data at high speeds allows for faster and more reliable diagnoses, which can facilitate quicker patient enrollment in clinical trials and accelerate the development of new treatments. As healthcare systems continue to evolve and rely on AI technologies to manage the growing complexity of medical data, the demand for AI-driven diagnostic solutions is expected to expand. Diagnostic companies investing in AI technologies and forming strategic collaborations to enhance these capabilities will be well-positioned to lead in the rapidly advancing Biopreservation market, driving both innovation and growth in the sector.

How can this report add value to an organization?

Product/Innovation Strategy: The global biopreservation market has been divided into several key segments, including product type, application, end users, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers valuable insights for organizations looking to innovate and expand their biopreservation product and technology offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the biopreservation market. Key developments and partnerships among biopreservation solution providers, biobanks, pharmaceutical and biotechnology companies, and research institutions form a significant part of the evolving market dynamics.

Competitive Strategy: The Biopreservation market is highly competitive, with numerous well-established players offering a wide range of biopreservation media, equipment, and services. Key market players are actively developing and adopting advanced cryopreservation technologies, automation, and digital monitoring solutions to differentiate themselves and strengthen their market position.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2035 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2025 to 2035 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts across various sectors, including biobanks and gene banks, pharmaceutical and biotechnology companies, cell and gene therapy developers, hospitals, academic research institutions, and CROs.
  • The market contribution of biopreservation products is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing commercially available biopreservation media, equipment. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in Biopreservation, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • BioLife Solutions, Inc.
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Azenta, Inc.
  • Bio-Techne
  • Cryoport Systems, LLC
  • Danaher Corporation (Cytiva)
  • PHC Corporation
  • Alpha Teknova, Inc.
  • Eppendorf SE
  • ThermoGenesis
  • OriGen Biomedical, Inc.
  • X-Therma, Inc.
  • STEMCELL Technologies
  • IC Biomedical, LLC

Table of Contents

Executive Summary

Scope and Definition

1 Global Biopreservation Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview
    • 1.1.2 Supply Chain Analysis
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Rapid Adoption of Advanced Cryopreservation Techniques
    • 1.2.3 Growing Integration of Artificial Intelligence and LIMS in Biobanking and Biospecimen Management
  • 1.3 Regulatory Landscape
    • 1.3.1 U.S.
      • 1.3.1.1 Regulatory Requirements for Biopreservation Media
      • 1.3.1.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
    • 1.3.2 Europe
      • 1.3.2.1 Regulatory Requirements for Biopreservation Media
      • 1.3.2.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 Japan
        • 1.3.3.1.1 Regulatory Requirements for Biopreservation Media
        • 1.3.3.1.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
      • 1.3.3.2 China
        • 1.3.3.2.1 Regulatory Requirements for Biopreservation Media
        • 1.3.3.2.2 Regulatory Requirements for Equipment Products Intended as Medical Devices
  • 1.4 Market Dynamics
    • 1.4.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.4.2 Market Drivers
      • 1.4.2.1 Expansion of Cell and Gene Therapies and Regenerative Medicine
      • 1.4.2.2 Growing Investments and Funding for Biobanks
    • 1.4.3 Market Challenges
      • 1.4.3.1 High Capital and Operating Costs of Advanced Biopreservation Infrastructure
      • 1.4.3.2 Operational Risk from Freezer Failures and Cryogenic Supply Disruptions
    • 1.4.4 Market Opportunities
      • 1.4.4.1 Global Shift toward Automated, Robotics-Enabled Cryogenic Storage Systems

2 Product Type

  • 2.1 Overview
    • 2.1.1 Equipment
      • 2.1.1.1 Freezers
      • 2.1.1.2 Refrigerators
      • 2.1.1.3 Cryogenic Storage Systems
      • 2.1.1.4 Others
    • 2.1.2 Media
      • 2.1.2.1 Hypothermic Preservation Media
      • 2.1.2.2 Cryopreservation Media

3 Application

  • 3.1 Overview
    • 3.1.1 Research Applications
    • 3.1.2 Therapeutic Applications
    • 3.1.3 Other Applications

4 End User

  • 4.1 Overview
    • 4.1.1 Biobanks and Gene Banks
    • 4.1.2 Hospitals
    • 4.1.3 Pharmaceutical and Biotech Companies
    • 4.1.4 Contract Research Organizations (CROs)
    • 4.1.5 Others

5 Region

  • 5.1 Regional Summary
  • 5.2 North America
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 Market Sizing and Forecast
    • 5.2.5 U.S.
      • 5.2.5.1 Country Overview
      • 5.2.5.2 Market Sizing and Forecast
    • 5.2.6 Canada
      • 5.2.6.1 Country Overview
      • 5.2.6.2 Market Sizing and Forecast
  • 5.3 Europe
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 Market Sizing and Forecast
    • 5.3.5 U.K.
      • 5.3.5.1 Country Overview
      • 5.3.5.2 Market Sizing and Forecast
    • 5.3.6 Germany
      • 5.3.6.1 Country Overview
      • 5.3.6.2 Market Sizing and Forecast
    • 5.3.7 France
      • 5.3.7.1 Country Overview
      • 5.3.7.2 Market Sizing and Forecast
    • 5.3.8 Italy
      • 5.3.8.1 Country Overview
      • 5.3.8.2 Market Sizing and Forecast
    • 5.3.9 Spain
      • 5.3.9.1 Country Overview
      • 5.3.9.2 Market Sizing and Forecast
    • 5.3.10 Rest-of-the- Europe
      • 5.3.10.1 Country Overview
      • 5.3.10.2 Market Sizing and Forecast
  • 5.4 Asia Pacific
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 Market Sizing and Forecast
    • 5.4.5 China
      • 5.4.5.1 Country Overview
      • 5.4.5.2 Market Sizing and Forecast
    • 5.4.6 Japan
      • 5.4.6.1 Country Overview
      • 5.4.6.2 Market Sizing and Forecast
    • 5.4.7 India
      • 5.4.7.1 Country Overview
      • 5.4.7.2 Market Sizing and Forecast
    • 5.4.8 Australia
      • 5.4.8.1 Country Overview
      • 5.4.8.2 Market Sizing and Forecast
    • 5.4.9 South Korea
      • 5.4.9.1 Country Overview
      • 5.4.9.2 Market Sizing and Forecast
    • 5.4.10 Rest-of-the-Asia Pacific
      • 5.4.10.1 Country Overview
      • 5.4.10.2 Market Sizing and Forecast
  • 5.5 Rest-of-the-World
    • 5.5.1 Regional Overview
    • 5.5.2 Driving Factors for Market Growth
    • 5.5.3 Factors Challenging the Market
    • 5.5.4 Market Sizing and Forecast

6 Competitive Benchmarking and Company Profiles

  • 6.1 Key Strategies and Developments, 2023-2025
  • 6.2 Key Developments Analysis (by Company), 2025
  • 6.3 Company Profiles
    • 6.3.1 BioLife Solutions, Inc.
      • 6.3.1.1 Overview
    • 6.3.2 Thermo Fisher Scientific Inc.
      • 6.3.2.1 Overview
    • 6.3.3 Sartorius AG
      • 6.3.3.1 Overview
    • 6.3.4 Azenta, Inc.
      • 6.3.4.1 Overview
    • 6.3.5 Bio-Techne
      • 6.3.5.1 Overview
    • 6.3.6 Cryoport Systems, LLC
      • 6.3.6.1 Overview
    • 6.3.7 Danaher Corporation (Cytiva)
      • 6.3.7.1 Overview
    • 6.3.8 PHC Corporation
      • 6.3.8.1 Overview
    • 6.3.9 Alpha Teknova, Inc.
      • 6.3.9.1 Overview
    • 6.3.10 Eppendorf SE
      • 6.3.10.1 Overview
    • 6.3.11 ThermoGenesis
      • 6.3.11.1 Overview
    • 6.3.12 OriGen Biomedical, Inc.
      • 6.3.12.1 Overview
    • 6.3.13 X-Therma, Inc.
      • 6.3.13.1 Overview
    • 6.3.14 STEMCELL Technologies
      • 6.3.14.1 Overview
    • 6.3.15 IC Biomedical, LLC
      • 6.3.15.1 Overview

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Inclusion and Exclusion
    • 7.1.4 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Biopreservation Market (by Scenario), $Million, 2024, 2025, and 2035
  • Figure 2: Global Biopreservation Market, 2024 and 2035
  • Figure 3: Global Biopreservation Market (by Country), $Million, 2024
  • Figure 4: Global Biopreservation Market Snapshot
  • Figure 5: Global Biopreservation Market, $Million, 2024 and 2035
  • Figure 6: Biopreservation Market (by Product Type), $Million, 2024, 2028, and 2035
  • Figure 7: Biopreservation Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 8: Biopreservation Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 9: Biopreservation Market Segmentation
  • Figure 10: Application of AI in Biobanking
  • Figure 11: Global Biopreservation Market (by Product Type), $Million, 2024, 2028, and 2035
  • Figure 12: Global Biopreservation Market (by Equipment), $Million, 2024-2035
  • Figure 13: Global Biopreservation Market (Freezers), $Million, 2024-2035
  • Figure 14: Global Biopreservation Market (Refrigerators), $Million, 2024-2035
  • Figure 15: Global Biopreservation Market (Cryogenic Storage Systems), $Million, 2024-2035
  • Figure 16: Global Biopreservation Market (Others), $Million, 2024-2035
  • Figure 17: Global Biopreservation Market (by Media), $Million, 2024-2035
  • Figure 18: Global Biopreservation Market (Hypothermic Preservation Media), $Million, 2024-2035
  • Figure 19: Global Biopreservation Market (Cryopreservation Media), $Million, 2024-2035
  • Figure 20: Global Biopreservation Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 21: Global Biopreservation Market (Research Applications), $Million, 2024-2035
  • Figure 22: Global Biopreservation Market (Therapeutic Applications), $Million, 2024-2035
  • Figure 23: Global Biopreservation Market (Other Applications), $Million, 2024-2035
  • Figure 24: Global Biopreservation Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 25: Global Biopreservation Market (Biobanks and Gene Banks), $Million, 2024-2035
  • Figure 26: Global Biopreservation Market (Hospitals), $Million, 2024-2035
  • Figure 27: Global Biopreservation Market (Pharmaceutical and Biotech Companies), $Million, 2024-2035
  • Figure 28: Global Biopreservation Market (Contract Research Organizations (CROs)), $Million, 2024-2035
  • Figure 29: Global Biopreservation Market (Others), $Million, 2024-2035
  • Figure 30: North America Biopreservation Market, $Million, 2024-2035
  • Figure 31: U.S. Biopreservation Market, $Million, 2024-2035
  • Figure 32: Canada Biopreservation Market, $Million, 2024-2035
  • Figure 33: Europe Biopreservation Market, $Million, 2024-2035
  • Figure 34: U.K. Biopreservation Market, $Million, 2024-2035
  • Figure 35: Germany Biopreservation Market, $Million, 2024-2035
  • Figure 36: France Biopreservation Market, $Million, 2024-2035
  • Figure 37: Italy Biopreservation Market, $Million, 2024-2035
  • Figure 38: Spain Biopreservation Market, $Million, 2024-2035
  • Figure 39: Rest-of-Europe Biopreservation Market, $Million, 2024-2035
  • Figure 40: Asia-Pacific Biopreservation Market, $Million, 2024-2035
  • Figure 41: China Biopreservation Market, $Million, 2024-2035
  • Figure 42: Japan Biopreservation Market, $Million, 2024-2035
  • Figure 43: India Biopreservation Market, $Million, 2024-2035
  • Figure 44: Australia Biopreservation Market, $Million, 2024-2035
  • Figure 45: South Korea Biopreservation Market, $Million, 2024-2035
  • Figure 46: Rest-of-Asia-Pacific Biopreservation Market, $Million, 2024-2035
  • Figure 47: Rest-of-the-World Biopreservation Market, $Million, 2024-2035
  • Figure 48: Key Strategies and Developments, 2023-2025
  • Figure 49: Inclusion and Exclusion Criteria for the Global Biopreservation Market
  • Figure 50: Data Triangulation
  • Figure 51: Top-Down and Bottom-Up Approach
  • Figure 52: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Biopreservation Market (by Region), $Million, 2024-2035
  • Table 3: Key Strategies and Developments, 2025